FBXW7 and peeling skin syndrome: AGO-Abs have the potential to identify novel biomarkers for diseases and have been identified in patients with systemic lupus erythematosus, scleroderma, dermatomyositis, and primary Sjögren’s syndrome (pSS), revealing a link with system autoimmunity, sensory neuronopathies, limbic encephalitis, cerebellar syndrome, opsoclonus–myoclonus, length-dependent polyneuropathies (8–11), and NMOSD (12).